JP Morgan Maintains Overweight on Akero Therapeutics, Lowers Price Target to $41
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph has maintained an Overweight rating on Akero Therapeutics (NASDAQ:AKRO) but lowered the price target from $62 to $41.
October 11, 2023 | 7:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan has maintained an Overweight rating on Akero Therapeutics but lowered the price target from $62 to $41.
The lowering of the price target by JP Morgan, a major financial institution, could negatively impact investor sentiment towards Akero Therapeutics, potentially leading to a short-term decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100